Author:
Thompson Gilbert,Parhofer Klaus G.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference64 articles.
1. Stefanutti C, Thompson GR. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17:465.
2. Myant NB. Plasma cholesterol as a cause of coronary heart disease (CHD); the cholesterol - CHD hypothesis. In: Reynolds LM, editor. Wellcome witnesses to twentieth century medicine, vol. 27. London: The Wellcome Trust; 2006.
3. de Gennes JL, Touraine R, Maunand B, Truffert J, Laudat P. [Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis an heroic treatment]. Bull Mem Soc Med Hop Paris. 1967;118:1377–402.
4. •• Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1:1208–11 First report demonstrating that cholesterol can be lowered by extracorporeal treatment modality. The study also included 14
C- cholesterol turnover experiments, elucidating the pathway of cholesterol removal.
5. •• Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet. 1981;2:1005–7 First selective apheresis device to decrease LDL-cholesterol. The method is based on binding apoB containing lipoproteins to a column and thus eliminating LDL particles from plasma.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献